Updates are available Correction dated 2020-06-25
Click to view Correction: https://doi.org/10.1038/s41591-020-0976-3
-
Authors
Slyper, Michal
Porter, Caroline B. M.
Ashenberg, Orr
Waldman, Julia
Drokhlyansky, Eugene
Wakiro, Isaac
Smillie, Christopher
Smith-Rosario, Gabriela
Wu, Jingyi
Dionne, Danielle
Vigneau, Sébastien
Jané-Valbuena, Judit
Tickle, Timothy L.
Napolitano, Sara
Su, Mei-Ju
Patel, Anand G. https://orcid.org/0000-0002-1438-8275
Karlstrom, Asa https://orcid.org/0000-0003-3847-7309
Gritsch, Simon
Nomura, Masashi https://orcid.org/0000-0001-6095-7849
Waghray, Avinash
Gohil, Satyen H.
Tsankov, Alexander M.
Jerby-Arnon, Livnat
Cohen, Ofir
Klughammer, Johanna
Rosen, Yanay
Gould, Joshua https://orcid.org/0000-0001-9581-5461
Nguyen, Lan
Hofree, Matan
Tramontozzi, Peter J. https://orcid.org/0000-0002-5540-0111
Li, Bo
Wu, Catherine J. https://orcid.org/0000-0002-3348-5054
Izar, Benjamin
Haq, Rizwan https://orcid.org/0000-0002-1290-9276
Hodi, F. Stephen
Yoon, Charles H.
Hata, Aaron N.
Baker, Suzanne J.
Suvà, Mario L. https://orcid.org/0000-0001-9898-5351
Bueno, Raphael
Stover, Elizabeth H. https://orcid.org/0000-0002-6578-3216
Clay, Michael R. https://orcid.org/0000-0003-1659-8927
Dyer, Michael A.
Collins, Natalie B.
Matulonis, Ursula A.
Wagle, Nikhil https://orcid.org/0000-0003-3332-9438
Johnson, Bruce E.
Rotem, Asaf
Rozenblatt-Rosen, Orit https://orcid.org/0000-0001-6313-3570
Regev, Aviv https://orcid.org/0000-0003-3293-3158
- License Information
-
More Information
Article History
Received: 13 August 2019
Accepted: 20 March 2020
First Online: 11 May 2020
Change Date: 25 June 2020
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41591-020-0976-3
Competing interests
: A. Regev is a founder of and equity holder in Celsius Therapeutics, an equity holder in Imunitas, and a SAB member of Syros Pharmaceuticals, Thermo Fisher Scientific, Asimov and NeoGene Therapeutics. M.S., O.A., E.D., O.R.-R. and A. Regev are co-inventors on patent applications filed by the Broad Institute for inventions relating to work in this manuscript, such as in PCT/US2018/060860 and US provisional application no. 62/745,259. C.J.W. is a founder and member of the scientific advisory board of Neon Therapeutics and receives research funding from Pharmacyclics. A. Rotem is a consultant and equity holder in Celsius Therapeutics. F.S.H. reports grants, personal fees from Bristol-Myers Squibb and Novartis and personal fees from Merck, EMD Serono, Takeda, Surface, Genentech/Roche, Compass Therapeutics, Apricity, Bayer, Aduro, Sanofi, Pfizer, Pionyr, Verastem, Torque and Rheos. In addition, F.S.H. has a patent ‘Methods for Treating MICA-Related Disorders’ (#20100111973) with royalties paid, a patent ‘Tumor Antigens and Uses Thereof’ (#7250291) issued, a patent ‘Angiopoiten-2 Biomarkers Predictive of Anti-immune Checkpoint Response’ (#20170248603) pending, a patent ‘Compositions and Methods for Identification, Assessment, Prevention and Treatment of Melanoma using PD-L1 Isoforms’ (#20160340407) pending, a patent ‘Therapeutic Peptides’ (#20160046716) pending, a patent ‘Therapeutic Peptides’ (#20140004112) pending, a patent ‘Therapeutic Peptides’ (#20170022275) pending, a patent ‘Therapeutic Peptides’ (#20170008962) pending, a patent ‘Therapeutic Peptides’ (patent no. 9402905) issued and a patent Methods of using ‘Pembrolizumab and Trebananib’ pending. R.H. has received research support from Novartis and Bristol-Myers and is a consultant for Tango Therapeutics. R.B. has received research support from Roche, Genentech, Merck, Siemens, Verastem, Gritstone, Epizyme, Medgenome and HTG and has equity in Navigation Sciences. A.N.H. has received research support from Novartis, Amgen, Pfizer, Roche/Genentech and Relay Therapeutics. B.I. is a paid consultant for Merck. U.A.M. received consulting fees from Novartis and Merck.
